Navigation Links
Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
Date:5/19/2009

INDIANAPOLIS, May 19 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today announced that it will be reporting Phase I clinical data on its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Florida, May 29 through June 2, 2009.

The presentation for Semafore's vascular targeted pan-PI3K/mTOR inhibitor is scheduled as follows:

    Time:        Saturday, May 30, 2009: 8:00 a.m. - 12:00 p.m. EDT
    Poster       Phase I evaluation of SF1126 a vascular targeted PI3K
    Title:       inhibitor administered twice weekly IV in patients with
                 refractory solid tumors
    Presenter:   Elena G. Chiorean, MD
    Location:    Level 2 - West Hall C. Poster Session Track: #79
                 Developmental Therapeutics: Cytotoxic Chemotherapy; Poster
                 Board B19 (Abstract # 2558)

About SF1126

SF1126 is the only clinical stage vascular targeted pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to specific integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment.

In preclinical xenograft models SF1126 has demonstrated broad activity as a single agent; synergy with commonly used chemotherapy agents, targeted agents, and radiation; and has been shown to reverse resistance mediated through the PI3K/PTEN pathway.

About PI3 Kinase

Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major pathways of intracellular signal transduction and are important in controlling cell growth/angiogenesis, d
'/>"/>

SOURCE Semafore Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data
2. U.S. Naval Medical Research Center Proposed RESUS Clinical Trial in Trauma Patients Remains on FDA Hold
3. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
4. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
5. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
9. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
10. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
11. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Fla. , Aug. 1, 2014 Dyadic ... whose patented and proprietary technologies are used to develop, ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... the second quarter ended June 30, 2014 after market ... a conference call that day at 5:00 p.m. Eastern ...
(Date:7/31/2014)... , July 31, 2014  According to data released ... the 2015 average monthly Medicare Part D premium is ... lower than was originally projected, the Pharmaceutical Care Management ... program continues to be a bright spot in American ... in each region and using cutting edge, cost-saving tools ...
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... ALLEGAN, Mich., May 10, 2011 Perrigo Company (Nasdaq: ... to settle all Hatch-Waxman litigation relating to fluticasone lotion brought ... relevant patents. Under the terms of the settlement, Perrigo can ... 22, 2012, or earlier under certain circumstances. ...
... Tenn., May 10, 2011 MedQuist Holdings Inc. (NASDAQ: ... transcription services and technology-enabled clinical documentation workflow solutions, today ... St. Joseph,s Hospital Health Center in Syracuse, New York, ... projected to achieve significant cost savings and improve efficiency ...
Cached Medicine Technology:Perrigo Announces Settlement of Cutivate Lotion Litigation 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 3
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... NV (PRWEB) August 01, 2014 ... opportunities for independent community pharmacies. At ThoughtSpot 2014, ... are equipped with practices and resources to enhance ... AmerisourceBergen leaders focused on critical issues to give ... optimize and grow. , ThoughtSpot show attendance ...
(Date:8/1/2014)... Dallas, Texas (PRWEB) August 01, 2014 ... universal health coverage and healthcare reforms are boosting ... price of medicines through discounts and increasing generic ... stood at approximately 76.7 million in 2013, having ... of 1.4%, from 2008. The implementation of the ...
(Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... importance of a nutritious lunch towards maintaining a healthy ... Commonwealth Games gold medal marathon runner// and mother of ... Dr John Tickell, and award-winning chef Michael Moore. ... to encourage Australians to make a healthy lunch a ...
... which are mainly used to prevent blocking of various arteries ... patients require other procedures// such as angioplasty or a by ... flexible nickel-titanium tubes. They are very effective in ... Researchers conducted a new study and published it in the ...
... that they are requesting patients to take a blood ... for a blood test for HIV and Hepatitis. Scripps ... nurse had failed to follow proper sterilization procedures for ... the so-called stomach-stapling operations. The instrument requires a different ...
... look into the costs of healthcare, met in Adelaide, and ... extremely high and has no system of prioritising patients. ... reason for wanting her breasts reduced has to wait just ... aesthetic reasons. Women who were in need for the surgery ...
... meet this week in Abuja, Nigeria, to review the progress ... malaria, tuberculosis. ,Five years ago the leaders had ... 15 per cent of national budgets in order to accelerate ... as other diseases. ,However progress has been dismal. ...
... carry a potential risk of suffering asthma, than compared to ... is published in the May 1 issue of Environmental Health ... 75 meters (about 82 yards) of a major road had ... in the past year than were children who lived more ...
Cached Medicine News:Health News:Celebrities Promote Healthy Lunch 2Health News:Waiting Period Of Over 10yrs For Women Needing Breast Reduction Surgery 2Health News:Review of Reversal of Spread of Diseases in Africa 2Health News:Asthma Risk Pronounced In Children Living Close to Traffic Ridden Roads 2
... EasyID is a patient identification ... cost savings by eliminating embossers, imprinters ... efficiency and workflow throughout the facility. ... patient identification and is designed to ...
The Metrologic MS9520 Voyager is a high performance single line laser bar code scanner with automatic activation and sophisticated data transmission via Metrologic proprietary CodeGate technology....
... latex-free, thermal transfer wristband for printing ... images that resist smears and abrasion ... cleaners, and blood. A time-tested and ... patron management applications. A tamper-evident VOID ...
... Durable, secure, direct thermal wristband ... entertainment venue patron admissions. Its clip ... five colors plus white for color ... Zebra printers for peak performance. Print ...
Medicine Products: